Abstract
Visfatin is highly expressed in adipose tissue (mainly by the stromal cells), but it is also ubiquitously present in most tissues. Visfatin, which plays a role in nicotinamide adenine dinucleotide (NAD) biosynthesis, has been implicated in inflammatory states. Controversial results exist about the expression, circulating levels and the role of visfatin in atherosclerosis-related diseases. Most studies showed increased levels of visfatin in diabetes mellitus, obesity, hypertension, renal and cardiovascular disease. However, other studies reported lower levels of visfatin in these diseases. The discrepancies in clinical studies may be attributed to the multifactorial regulation of visfatin. There is evidence that visfatin expression and circulating levels are influenced by fat area and distribution, inflammatory state, renal function, iron metabolism, hormones as well as several other factors. Furthermore, discrepancies and lack of correlation between commercially available visfatin assays have been reported. More research is needed to better understand the factors that control its synthesis/release and to evaluate the role of visfatin in atherosclerosis-related disease. Large studies with homogeneous populations will probably be needed to answer these questions. Whether visfatin will eventually become a therapeutic target remains to be established.
Keywords: Visfatin, atherosclerosis, diabetes mellitus, obesity, dyslipidaemia, hypertension, renal disease, cardiovascular disease
Current Vascular Pharmacology
Title: Visfatin/PBEF and Atherosclerosis-Related Diseases
Volume: 8 Issue: 1
Author(s): Theodosios D. Filippatos, Harpal S. Randeva, Christos S. Derdemezis, Moses S. Elisaf and Dimitri P. Mikhailidis
Affiliation:
Keywords: Visfatin, atherosclerosis, diabetes mellitus, obesity, dyslipidaemia, hypertension, renal disease, cardiovascular disease
Abstract: Visfatin is highly expressed in adipose tissue (mainly by the stromal cells), but it is also ubiquitously present in most tissues. Visfatin, which plays a role in nicotinamide adenine dinucleotide (NAD) biosynthesis, has been implicated in inflammatory states. Controversial results exist about the expression, circulating levels and the role of visfatin in atherosclerosis-related diseases. Most studies showed increased levels of visfatin in diabetes mellitus, obesity, hypertension, renal and cardiovascular disease. However, other studies reported lower levels of visfatin in these diseases. The discrepancies in clinical studies may be attributed to the multifactorial regulation of visfatin. There is evidence that visfatin expression and circulating levels are influenced by fat area and distribution, inflammatory state, renal function, iron metabolism, hormones as well as several other factors. Furthermore, discrepancies and lack of correlation between commercially available visfatin assays have been reported. More research is needed to better understand the factors that control its synthesis/release and to evaluate the role of visfatin in atherosclerosis-related disease. Large studies with homogeneous populations will probably be needed to answer these questions. Whether visfatin will eventually become a therapeutic target remains to be established.
Export Options
About this article
Cite this article as:
Filippatos D. Theodosios, Randeva S. Harpal, Derdemezis S. Christos, Elisaf S. Moses and Mikhailidis P. Dimitri, Visfatin/PBEF and Atherosclerosis-Related Diseases, Current Vascular Pharmacology 2010; 8 (1) . https://dx.doi.org/10.2174/157016110790226679
DOI https://dx.doi.org/10.2174/157016110790226679 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
From Test Tube to Clinical Trial; Promising Herbs with NF-κB and COX- 2 Activity
Current Immunology Reviews (Discontinued) IGF-I Abuse in Sport
Current Drug Abuse Reviews Antioxidant Therapy for Prevention of Inflammation, Ischemic Reperfusion Injuries and Allograft Rejection
Cardiovascular & Hematological Agents in Medicinal Chemistry Histone Deacetylase Inhibitors Target Diabetes via Chromatin Remodeling or as Chemical Chaperones?
Current Diabetes Reviews Patent Selections
Recent Patents on Biomarkers Dipeptidyl Peptidase-4 Inhibition: Linking Chemical Properties to Clinical Safety
Current Medicinal Chemistry The Impact of Diabetes Mellitus on Coronary Artery Disease: New Therapeutic Approaches
Current Pharmaceutical Design Evaluation of Eudragit® Retard Polymers for the Microencapsulation of Alpha-Lipoic Acid
Current Drug Delivery Pregnancy and Sleep Apnea
Current Respiratory Medicine Reviews Voglibose (Basen®, AO-128), One of the Most Important α-Glucosidase Inhibitors
Current Medicinal Chemistry Targeting Nrf2 in Protection Against Renal Disease
Current Medicinal Chemistry Peripheral Artery Disease in Diabetes Mellitus: Focus on Novel Treatment Options
Current Pharmaceutical Design Molecular Players at the Intersection of Obesity and Osteoarthritis
Current Drug Targets Comparison of Biolimus Versus Everolimus for Drug-Eluting Stents in the Percutaneous Treatment of Infra-Inguinal Arterial Disease
Current Vascular Pharmacology The Use of Interferons in Respiratory Diseases
Current Respiratory Medicine Reviews Interactions of Biologically Active Factors and Vascular Mediators During Hypertension in Pregnancy
Current Hypertension Reviews The Shift in the “Paradigm” of the Pharmacology of Hypertension
Current Topics in Medicinal Chemistry Curcumin Reverts the Protein Differential Expression in the Liver of the Diabetic Obese db/db Mice
Current Proteomics Hypertension in Type 2 Diabetes Mellitus: Do We Need to Redefine the Role of Sulfonylureas?
Recent Advances in Cardiovascular Drug Discovery (Discontinued) Statins: A Valuable Tool for the Prevention/Regression of Abdominal Aortic Aneurysms
Vascular Disease Prevention (Discontinued)